NASDAQ:PTE • US7310942070
The current stock price of PTE is 0.241 USD. In the past month the price decreased by -36.91%. In the past year, price decreased by -85.39%.
ChartMill assigns a fundamental rating of 3 / 10 to PTE. PTE may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months PTE reported a non-GAAP Earnings per Share(EPS) of -2.41. The EPS increased by 61.44% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
5 analysts have analysed PTE and the average price target is 0.82 USD. This implies a price increase of 238.59% is expected in the next year compared to the current price of 0.241.
For the next year, analysts expect an EPS growth of 48.01% and a revenue growth -100% for PTE
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.98 | 410.174B | ||
| AMGN | AMGEN INC | 17.23 | 209.016B | ||
| GILD | GILEAD SCIENCES INC | 16.7 | 184.799B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.37 | 126.056B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.83 | 82.638B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.7 | 43.982B | ||
| INSM | INSMED INC | N/A | 31.848B | ||
| NTRA | NATERA INC | N/A | 28.947B | ||
| BIIB | BIOGEN INC | 12.61 | 28.152B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.1 | 21.698B |
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
PolarityTE, Inc. is a biotechnology company developing and commercializing regenerative tissue products and biomaterials. The company is headquartered in Salt Lake City, Utah and currently employs 42 full-time employees. Its first regenerative tissue product is SkinTE. Its SkinTE is intended for the repair, reconstruction, replacement, and supplementation of skin in patients who have a need for treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts. The firm's development projects include SkinTE Point-of-Care Device, SkinTE Cryo and Other Tissue Regeneration Products. SkinTE Cryo allows it to offer multiple deployments from one original harvest through a cryopreservation process. The core technology of SkinTE is minimally polarized functional units (MPFUs). MPFUs are multi-cellular segments created from a piece of the patient’s healthy skin.
POLARITYTE INC
1960 S. 4250 West
Salt Lake City UTAH 84116 US
CEO: David Seaburg
Employees: 42
Phone: 13852663151.0
PolarityTE, Inc. is a biotechnology company developing and commercializing regenerative tissue products and biomaterials. The company is headquartered in Salt Lake City, Utah and currently employs 42 full-time employees. Its first regenerative tissue product is SkinTE. Its SkinTE is intended for the repair, reconstruction, replacement, and supplementation of skin in patients who have a need for treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts. The firm's development projects include SkinTE Point-of-Care Device, SkinTE Cryo and Other Tissue Regeneration Products. SkinTE Cryo allows it to offer multiple deployments from one original harvest through a cryopreservation process. The core technology of SkinTE is minimally polarized functional units (MPFUs). MPFUs are multi-cellular segments created from a piece of the patient’s healthy skin.
The current stock price of PTE is 0.241 USD. The price decreased by -0.82% in the last trading session.
PTE does not pay a dividend.
PTE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
5 analysts have analysed PTE and the average price target is 0.82 USD. This implies a price increase of 238.59% is expected in the next year compared to the current price of 0.241.
POLARITYTE INC (PTE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.41).
You can find the ownership structure of POLARITYTE INC (PTE) on the Ownership tab.